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Abstract
Objectives
The existence of phenotypes has been hypothesized to explain the large heterogeneity
characterizing the knee osteoarthritis. In a previous systematic review of the literature, six
main phenotypes were identified: Minimal Joint Disease (MJD), Malaligned Biomechanical
(MB), Chronic Pain (CP), Inflammatory (I), Metabolic Syndrome (MS) and Bone and Carti-
lage Metabolism (BCM). The purpose of this study was to classify a sample of individuals
with knee osteoarthritis (KOA) into pre-defined groups characterized by specific variables
that can be linked to different disease mechanisms, and compare these phenotypes for
demographic and health outcomes.
Methods
599 patients were selected from the OAI database FNIH at 24 months’ time to conduct the
study. For each phenotype, cut offs of key variables were identified matching the results
from previous studies in the field and the data available for the sample. The selection pro-
cess consisted of 3 steps. At the end of each step, the subjects classified were excluded
from the further classification stages. Patients meeting the criteria for more than one pheno-
type were classified separately into a ‘complex KOA’ group.
Results
Phenotype allocation (including complex KOA) was successful for 84% of cases with an
overlap of 20%. Disease duration was shorter in the MJD while the CP phenotype included
a larger number of Women (81%). A significant effect of phenotypes on WOMAC pain (F =
16.736 p <0.001) and WOMAC physical function (F = 14.676, p < 0.001) was identified after
controlling for disease duration.
Conclusion
This study signifies the feasibility of a classification of KOA subjects in distinct phenotypes
based on subgroup-specific characteristics.
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1. Introduction
Osteoarthritis (OA) is the most common form of arthritis and the knee is the most commonly
affected joint [1]. The knee osteoarthritis (KOA) patient population is highly heterogeneous.
To better explain this heterogeneity it has been suggested that a multitude of underlying mech-
anisms leading to similar clinical presentations (joint damage, pain, stiffness and loss of physi-
cal function) are responsible for the development and progression of KOA[2,3]; in other
words, the KOA population comprises a number of distinct subgroups, or phenotypes[2,4,5].
Different approaches to phenotype identification in the KOA population have been advo-
cated. Felson et al. suggested that phenotype research should be focused on those subgroups
that could influence treatment allocation and management of the disease[5]. Several authors
have attempted to identify meaningful clinical phenotypes of the disease[6] A common
approach emerging from the literature is to use risk or etiologic factors (e.g. obesity, skeletal
malalignment, depression) to identify groups characterized by major hypothesised underlying
mechanisms (e.g. pain sensitisation, excessive joint load, metabolic changes).
A recent systematic review summarized these studies[6], suggesting the existence of specific
sets of variables that describe subgroups characterised by: unusual inflammation profiles inside
the knee joint; sensitisation to pain and pain neurophysiology alterations (e.g. generalized
hypersensitivity to pain and temporal summation); adverse biomechanics where the knee
malalignment is severe enough to drive the disease in absence of other known risk factors; sys-
temic metabolic disorders (e.g. obesity, diabetes); and changes in bone and cartilage metabo-
lism in the knee, as well as a phenotype of minimal joint disease with minor symptoms and
discomfort over an extensive period of time.
A next essential step in the development of a feasible and useful phenotypic sub-classifica-
tion of KOA is to establish whether individual patients can be correctly assigned to these phe-
notypes. Assigning a phenotype should then enable better clinical decision making with
respect to optimal treatment strategies[7–9]. Additionally, the phenotypes previously identi-
fied are not necessarily mutually exclusive, i.e. the key characteristics of more than one pheno-
type could be present in the same patient. This raises the question whether this group of poly-
phenotypical patients, or ‘complex KOA’ cases, is characterised by a more severe disease status
and course.
The purpose of this study was to classify a sample of individuals with KOA into pre-defined
groups characterized by specific characteristics that can be linked to different disease mecha-
nisms and/or targeted by tailored treatments (e.g. subjects with malalignment only, in absence
of other risk factors, may be considered belonging to a malaligned biomechanical phenotype)
Secondly, these groups of patients were then compared for demographic and health out-
comes (Western Ontario and McMaster Universities Osteoarthritis Index [WOMAC] pain,
WOMAC physical function) to identify differences in severity and prognosis between pheno-
types. Of particular interest was the group of ‘complex KOA’ patients who met the criteria for
more than one phenotype.
2. Methods
2.1 Study population
Data were obtained from the Osteoarthritis Initiative (OAI) database, a multi-centre prospec-
tive longitudinal cohort study designed to identify biomarkers and risk factors associated with
the incidence and progression of KOA (http://www.oai.ucsf.edu/)[10]. As part of the OAI, par-
ticipants aged 45–79 years with, or at risk of, symptomatic KOA in at least one knee were
recruited from four centres in the United States.
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Data from the OA Biomarkers Consortium FNIH Project was used as the sample source for
the current study. The FNIH study includes 600 subjects from the OAI dataset with availability
at baseline and 24 months of knee radiographs, knee magnetic resonance images (MRI), stored
serum and urine specimens and clinical data. Knees were not included in the FNIH cohort if
they received a joint replacement before the 24 months follow up, had a minimum medial
joint space width <1.0mm and/or WOMAC pain>91 on 0–100 scale. For the current study,
the 24 month follow up was selected for the larger availability of data. We selected OAI partici-
pants who had: (1) Kellgren & Lawrence grade (K&L)1; (2) availability of Magnetic Reso-
nance Imaging Osteoarthritis Knee Score (MOAKS) score data; and (3) serum and urine
biomarkers of bone and cartilage metabolism. MRI assessment in the selected cohort was per-
formed unilaterally; therefore the index knee was the one with the availability of MOAKS
score[11].
2.2 Selection of the variables for the classification process
Six main sets of variables suggesting the existence of clinical KOA phenotypes were identified
through a previous search of the literature[6] (Table 1). In order to design the classification
process, cut-off values were identified for each of these sets of variables and used to determine
the phenotype membership of each subject. Where possible, validated cut-offs already used in
OA research or clinical practice were adopted (e.g. Centre for Epidemiologic Studies Depres-
sion scale [CES-D], malalignment). Where existing cut-offs were not available, specific values
were determined based on variables distribution in the selected sample (Table 1). For a
detailed description of the variables see S1 Table.
2.3 Classification process
The classification process consisted of three stages. For an overview of the classification pro-
cess see Fig 1. In the first stage, the Minimal Joint Disease (MJD) phenotype was identified
starting from the whole sample. Subjects included in the MJD phenotype represent a subgroup
with low to mild symptomatology which is stable over time and is associated with minor health
care needs[5]. For these reasons, we chose to classify subjects in the MJD phenotype in the first
stage and exclude them from the following classification steps. In the second stage, cut-offs
were designed to classify subjects in the remaining five phenotypes. The cut-offs used at this
stage were characterized by high specificity in order to minimize false positive results. In the
third step, the cut-offs previously applied were modified to increase their sensitivity in order to
allocate the subjects not yet classified after the first two steps. This last step was included to
minimize false negative results in subjects not classified in the previous step due to the high
specificity of the criteria. The risk of false positives at this stage was reduced since the sensitive
criteria were applied only to the subjects not classified in the previous steps. Any remaining
patient not allocated to a phenotype after the third step was regarded as not fitting in any of
the phenotypic subgroups (‘NON-CLASSIFIED’ group). In the second and third steps, the
subjects who met the criteria for more than one phenotype were allowed to overlap and were
grouped together in a separate group named ‘complex KOA’. This three-step design allowed
us to classify the highest possible number of subjects limiting the excessive overlap that would
emerge from the use of only sensitive criteria and avoiding the classification of subjects in
small size groups that would result from the use of only specific criteria.
2.4 Minimal joint disease phenotype (MJD)
A combination of low level of self-reported pain (worse pain in the last week 3/10; release
version 3.2.1) and mild to moderate radiographic OA (ROA) (K&L 2, release version 3.7)
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was chosen to classify subjects in the MJD phenotype (see Table 1). To ensure the inclusion of
subjects with minimal/no disease progression, exclusively for the MJD, the aforementioned
cut-offs were applied at both the 24- and 48- month OAI follow-up measurements (K&L
Table 1. Criteria used in the classification process.
Phenotype Specific cut-offs Sensitive cut-offs
MJD (Pain  3 AND K&L 2 at 24 months) AND (Pain 3 AND K&L 2 at
48 months).
-
I MOAKS score synovitis/effusion = 3 MOAKS score synovitis/effusion = 2
MD Presence of diabetes AND BMI 30 (Presence of diabetes OR BMI 30) AND (systolic pressure 140 mmHg
OR diastolic pressure 100 mmHg)
CP CESD-R 16 OR Tender points n˚ 6 located: above and below the waist,
on both sides of the body, and axially
CESD-R 16 OR Tender points n˚ 3 located above and below the waist
MB Valgus alignment2˚ AND MOAKS lateral tibial condyle 2.0 AND
MOAKS medial tibial condyle1.0) OR (Varus alignment2˚ AND
MOAKS lateral tibial condyle 1.0 AND MOAKS medial tibial
condyle 2.0)
Valgus alignment2˚ AND MOAKS lateral tibial condyle > MOAKS
score medial tibial condyle) OR (Varus alignment2˚ AND MOAKS
lateral tibial condyle < MOAKS score medial tibial condyle)
BCM (uNTXI, uCTXII, uCTX-1ß, uCTX-1α> 75th percentile) OR (sComp, sHA
>75th percentile)
(uNTXI, uCTXII, uCTX-1ß, uCTX-1α> 65th percentile) OR (sComp, sHA
>65th percentile)
Worse pain in the past seven days rated from 0–10
K&L: Kellgren & Lawrence
MOAKS: Magnetic Resonance Imaging Osteoarthritis Knee Score
MJD: minimal Joint Disease phenotype
I: Inflammatory phenotype
MD: Metabolic Disorder phenotype
CP: Chronic Pain phenotype
MB: Malaligned Biomechanical phenotype
BCM: Bone and Cartilage Metabolism phenotype
BMI: body mass index
CES-D: Center for Epidemiologic Studies Depression scale
uNTXI: Urine N-Terminal Telopeptide type I
uCTXII: C-Terminal Telopeptide type II
uCTX-1ß: C-Terminal Telopeptide type 1ß
uCTX-1α: C-Terminal Telopeptide type 1α
sComp: Serum Cartilage Oligomeric Matrix Protein
sHA: Serum Hyaluronic Acid
https://doi.org/10.1371/journal.pone.0191045.t001
Fig 1. Summary of the subjects classified in each classification phase.
https://doi.org/10.1371/journal.pone.0191045.g001
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release version 6.5, Self-reported pain release version 6.2.1). Eight subjects satisfying the inclu-
sion criteria at 24 month had K/L grade missing at 48 month. Only for these subjects, the fol-
lowing criteria were used to avoid misclassifications: (Worst self-reported pain in the last week
1 on a scale 0–10 at 24 months) AND (K&L score2 at t0) AND (Worst self-reported pain
in the last week1 on a scale 0–10 at 48 months).
2.5 Chronic pain phenotype(CP)
Depression is a common condition among subjects with a chronic painful disease such as
KOA where it has an important interaction with pain perception and functional decline[12].
Widespread pain represents an important indicator of enhanced pain sensitivity and central
sensitization and is associated with high level of pain in the KOA population[13]. A combina-
tion of depression and self-reported widespread pain (release 3.2.1) was used to classify
patients belonging to the chronic pain phenotype. A score of 16 in the CES-D was used as a
cut-off for depression in both specific and sensitive criteria since it has been associated with
clinically significant depressive symptoms[14]. Ten body areas (excluding the knees) were
identified to cover the areas used in the ACR criteria (1990) for widespread pain (Neck, left
shoulder, right shoulder, temporomandibular joint (jaw) either side, temporomandibular joint
across face/cheek, left elbow, right elbow, lower back, left hip, right hip). The presence of
depression and pain in at least 6 body spot located: above and below the waist, on both sides of
the body, and axially was used as cut-offs for the identification of widespread pain in the spe-
cific criterion. Presence of depression and 3 painful body areas located above and below the
waist was used as a sensitive criterion.
2.6 Malaligned biomechanical phenotype (MB)
Repeated evidence shows that knees sufficiently malaligned progress to worse disease without
the presence of other known risk factors[5]. Malalignment confers high focal stress that can
overcome the ability of cartilage within the joint to withstand it. Therefore, compartmental
degeneration consistent with the alignment of the lower limb may identify a KOA phenotype
in which biomechanical mechanisms are responsible for the disease[15,16]. For this reason,
malalignment and cartilage degeneration were the variables used to classify subjects in the
malaligned biomechanical phenotype. A variation of ±2˚ from the hip knee ankle angle,
assessed clinically with hand goniometer (release 3.2.1), was considered as malalignment, in
both the specific (step 2) and sensitive (step 3) criteria[17]. Cartilage degeneration was assessed
using the MOAKS score (Femoral compartment: cartilage area intra-rater reliability
kappa = 0.92, inter-rater reliability kappa = 0.62; tibial compartment: cartilage area intra-rater
reliability kappa = 0.73, inter-rater reliability kappa = 0.36) (release 3.1). For the purpose of
this study, only the central weight-bearing part of the tibial condyles was analysed since it
showed to be the most affected by OA degeneration (in the selected sample). The aforemen-
tioned cut-offs were combined in order to develop the specific and sensitive criteria. In the
specific criteria the MOAKS score for the most involved compartment was fixed at 2.0 (indi-
cating damage that involves between 10% and 75% of the cartilage surface without full-thick-
ness lesion) or higher while the less affected was fixed at 1.0 or lower (indicating damage that
involves less than 10% of the cartilage surface without full-thickness lesion). The most degen-
erated compartment had to be consistent with malalignment (e.g., higher damage in the
medial compartment with varus malalignment). In the sensitive criteria, no specific value for
the MOAKS score was selected, the only condition was that the compartment with the highest
level of degeneration was consistent with the malalignment.
Clinical phenotypes in knee osteoarthritis
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2.7 Inflammatory phenotype (I)
Synovitis is a strong indicator of the presence of inflammation processes and has been reported
as a key factor in an inflammatory phenotype[18]. The presence of synovitis was graded using
the MOAKS score (release 3.1) for synovitis/effusion on a scale from 0 (no effusion/synovitis)
to 3 (severe effusion/synovitis). Subjects with a MOAKS synovitis/effusion score of 3 (specific
criterion, step 2) and 2 (sensitive criterion, step 3) were included in the inflammatory
phenotype.
2.8 Metabolic disorders phenotype (MD)
Previous studies showed the existence of a phenotype in which the individuals are character-
ized by the presence of metabolic disorders (e.g. Obesity, diabetes, hypertension, dyslipidemia)
[18–22]. High BMI (30kg.m-2) and the presence of diabetes are two of the most common
metabolic disorders and have been shown to be related to a higher incidence of KOA and a
higher risk of knee replacement[23]. Therefore, in the present study, people with diabetes and
BMI30 kg/m2 were considered to belong to a metabolic disorder phenotype (MD). High
blood pressure is another recognized disorder part of the metabolic syndrome. However, it has
been shown to have only a weak association with KOA[24,25]. Recent studies suggested that
hypertension should only be considered an aggravating factor for OA in subjects with obesity
or other metabolic disorders[26]. For this reason, in order to increase the sensitivity of the cri-
terion, any one of the previous specific criteria in combination with high blood pressure/
hypertension (systolic pressure 140 mmHg OR diastolic pressure 100 mmHg) was consid-
ered sufficient to include a subject in the MD phenotype in the last, sensitive, step of the classi-
fication process.
2.9 Bone and cartilage metabolism (BCM)
Alterations in bone and cartilage metabolism have been identified in specific KOA subgroups
[18,27–29]. Biomarker analysis is the gold standard for the identification of metabolic alter-
ations of bone and cartilage. Van Spil et al. identified two subgroups of KOA subjects charac-
terised by an alteration in the bone and cartilage metabolism through a principal component
analysis [18]. The biomarkers available in the OAI dataset matching with the biomarkers char-
acterizing the two groups identified by van Spil et al. were extracted for the purpose of this
study (1: uNTXI, uCTXII, uCTX-1ß, uCTX-1α; 2: sComp, sHA) (release version 3.2.1). A con-
centration higher than the 75th percentile of each of the biomarkers of at least one of the sub-
groups was used as a specific cut-off to determine the membership to the bone and cartilage
metabolic phenotype in the first selection step. The cut-off was lowered to the 65th percentile
in the second step to increase its sensitivity.
2.10 Comparison of phenotypes for demographic and health outcomes
Differences in sex and additional variables including history of knee injury (defined as any
self-reported knee injury severe enough to limit the ability to walk for at least two days previ-
ous the 24 month visit), knee joint laxity and quadriceps strength were analysed in order to
better define the phenotypes. One variable for knee pain (WOMAC pain 24 month) [30] and
one variable for activity limitation (WOMAC function 24 month) [30] were used to assess dif-
ferences between the groups and regarded as a health outcome. A difference between groups
of 9 points on a 0–100 scale for WOMAC pain was considered clinically significant[31].
Clinical phenotypes in knee osteoarthritis
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2.12 Analysis
Subjects included in the same phenotype but in different steps of the classification process
were grouped and analysed as a single phenotype. Subjects classified in more than one pheno-
type were considered part of the complex KOA subgroup and analysed as a separate subgroup.
Subjects not classified in any of the phenotypes were considered and analysed as a separate
subgroup. A One-Way ANOVA with Bonferroni correction was conducted to analyse the dif-
ference in age and disease duration between the groups. A One-way ANCOVA was conducted
to determine whether a statistically significant difference existed between phenotypes on the
selected clinical variables (i.e. WOMAC pain, WOMAC physical function, muscle strength)
controlling for disease duration and use of pain medications for the knee symptoms. A post
hoc Sidak test was used to correct for multiple comparisons; p values and confidence intervals
were bootstrapped (bias-corrected accelerated 1000 samples). A Chi-square test was conducted
to test the relation between the categorical variables (e.g. gender, history of knee injury) and
phenotypes. Fisher’s exact test was used for the K&L score, laxity and synovitis. The cell counts
were compared across phenotypes using a z-test and a Bonferroni correction for multiple com-
parisons (significance value of p< 0.05). All the calculations were performed using IBM SPSS
statistics v22.
3. Results
For the purpose of the study, 599 subjects were selected (characteristics of the sample reported
in Table 2 and supplementary material 1A). Therefore, from the original sample of the FNIH
sub-cohort, only one subject presenting K&L grade<1 was excluded. In the first step of the
selection process, 149 of the 599 subjects were classified into the MJD phenotype. In the second
step, 255 of the 450 remaining subjects were classified in the other five phenotypes with an
overlap of 28.6% (73/255; 61 classified in 2 phenotypes, 12 classified in 3 phenotypes). In the
third step, 98 of the 195 remaining subjects were classified using the high sensitivity criteria
with an overlap of 29.6% (29/98, 24 classified in two phenotypes, five classified in three pheno-
types). At the end of the process, 502 subjects (83%) were classified in at least one phenotype
with a total overlap of 20% (102 out of 502). Ninety-seven subjects (17%) were not classified in
any phenotype at the end of the process (see Table 2). No specific pattern was identified in the
overlap among the phenotypes (Table 3).
No difference in mean age was identified (Table 4). The MJD phenotype showed a shorter
symptoms duration (p = 0.001) compared to the CP phenotype and the complex KOA sub-
group (P = 0.018), while no statistical difference was detected between the other phenotypes.
Sex was not equally distributed between all the phenotypes. The prevalence of women reached
81% in the CP phenotype while it was only 35% in the MB phenotype (p<0.05). No differ-
ences regarding sex distribution were found between the other groups.
There was a significant effect of phenotypes on WOMAC pain (F = 16.736 p = 0.001) and
WOMAC physical function (F = 14.674, p = 0.001) after controlling for disease duration and
use of pain medication (Table 5). The assumption of homogeneity of the regression slope was
not violated. Looking at the health outcomes, the MJD phenotype showed the lowest scores of
WOMAC pain and WOMAC physical function (p<0.05 compared to all other groups). The
CP phenotype presented the highest pain severity and lowest WOMAC physical function
score when compared with the other individual phenotypes (WOMAC pain p = 0.001 com-
pared to MJD and MB; WOMAC physical function p = 0.001 compared to MJD and MB, and
p = 0.03 compared to BCM). WOMAC pain score differences were also clinically significant.
The MB phenotype presents the second lowest score (after the MJD phenotype) for WOMAC
pain and physical function compared to the other phenotypes (WOMAC pain p = 0.001
Clinical phenotypes in knee osteoarthritis
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compared to MJD, CP; WOMAC physical function p = 0.001 compared to MJD, CP). The dif-
ference in pain between the MB and CP phenotype was above the threshold for clinical signifi-
cance. The I and MD phenotypes had similar scores in all the WOMAC areas (no significant
difference) while they had intermediate scores if compared with the other phenotypes. The
BCM phenotype had lower scores compared to the CP, I and MD phenotypes in all the
Table 2. Sample characteristics.
Variable N Mean SD
Age 599 63.6 8.8














Worse pain previous week 592 3 2.8
WOMAC synovitis/effusion
Serum Comp (ng/mL) 599 786.6 318.7
Serum HA (ng/mL) 599 67.9 64.6
Urine NTXI (nmol BCE) 599 253.2 192.0
Urine CTXII (ug/L) 599 2.6 2.3
Urine CTX-1a (ng/mL) 599 3.6 2.4
Urine CTX-1ß (ug/L) 599 17.4 15.8
BMI (kg.m-2) 597 30.7 4.8
Blood pressure: systolic (mm Hg) 597 124.6 15.3
Blood pressure: diastolic (mm Hg) 597 75.47 9.5
CES-D 592 6.82 6.8
Widespread pain 597 1.8 1.7
Quadriceps Strength 563 324.5 126.9
WOMAC physical function 599 9.5 11.3
WOMAC pain 599 3 3.5
BMI: body mass index
CES-D: Center for Epidemiologic Studies Depression scale
uNTXI: Urine N-Terminal Telopeptide type I
uCTXII: C-Terminal Telopeptide type II
uCTX-1ß: C-Terminal Telopeptide type 1ß
uCTX-1α: C-Terminal Telopeptide type 1α
sComp: Serum Cartilage Oligomeric Matrix Protein
sHA: Serum Hyaluronic Acid
nM BCE: nanomoles bone collagen equivalents
https://doi.org/10.1371/journal.pone.0191045.t002
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WOMAC areas; however, only the difference in WOMAC function with the CP phenotype
was significant (p = 0.03).
Table 3. Report of the overlap between phenotypes.
MJD (1) CP (2) MB (3) I (4) MD (5) BCM (6)
MJD (1) - - - - - -
CP (2) - 9 5 14 17
MB (3) - 4 5 10
I (4) - 1 13
MD (5) - 7
BCM (6) -
Subjects classified in three phenotypes: I+BCM+CP: 4, I+CP+ MD: 2, BCM+CP+MB: 6, MD+CP+MB: 3, BCM+MD
+MB: 1, BCM+MD+CP: 1; Total: 17
MJD: minimal Joint Disease phenotype
I: Inflammatory phenotype
MD: Metabolic Disorder phenotype
CP: Chronic Pain phenotype
MB: Malaligned Biomechanical phenotype
BCM: Bone and Cartilage Metabolism phenotype
https://doi.org/10.1371/journal.pone.0191045.t003
Table 4. Comparison of patient characteristics between groups.
PHENOTYPE MJD (1) CP (2) MB (3) I (4) MD (5) BCM (6) COMPLEX KOA (7) NON CLASS (8)
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Number 149 64 63 29 25 70 102 97
Age 63.1 (8.8) 63.4 (8.1) 65.6 (8.5) 63.0 (9.6) 61.7 (8.7) 65.3 (8.5) 63.5 (9.4) 62.9 (8.9)
Gender (female) 58%2,3 81%1,3,6 35%1,2,7 62% 60% 54%2 63%2 59%
Disease duration (years) 32,7 (1.7) 4.41 (2.2) 3.6 (2) 3.8 (2) 3.5 (1.8) 3.7 (2.0) 3.91 (2.1) 3.8 (2.0)
History of injuries 29.5% 46.9% 36.5% 44.8% 36.0% 35.7% 36.7% 39.2%
WOMAC physical function (0–100)† 7.0all (1.2) 20.31,3,6,8 (1.8) 11.01,2,7.
(1.8)





6.6all (1.2) 19.51,3,7,8 (1.9) 13.01,2,7 (1.8) 18.11,7 (2.7) 18.41,7 (2.9) 15.61,7 (1.8) 26.8all (1.5) 12.11,2,4,7 (1.5)
All: significantly different from all the other phenotypes (p < 0,05)
1: significantly different from phenotype 1 (MJD) (p < 0,05)
2: significantly different from phenotype 2 (CP) (p < 0,05)
3: significantly different from phenotype 3 (MB) (p < 0,05)
4: significantly different from phenotype 4 (I) (p < 0,05)
5: significantly different from phenotype 5 (MS) (p < 0,05)
6: significantly different from phenotype 6 (BCM) (p < 0,05)
7: Significantly different from group 7 (COMPLEX KOA) (p < 0,05)
8: Significantly different from group 8 (NON-CLASS.) (p < 0,05)
MJD: minimal Joint Disease phenotype
I: Inflammatory phenotype
MD: Metabolic disorder phenotype
CP: Chronic Pain phenotype
MB: Malaligned Biomechanical phenotype
BCM: Bone and Cartilage Metabolism phenotype
†: as result of the ANCOVA with disease duration and pain medication use as covariate the value reported represent the adjusted mean and standard error.
https://doi.org/10.1371/journal.pone.0191045.t004
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The complex KOA subgroup showed the worst score in all the WOMAC areas compared to
the other groups (WOMAC pain p< 0.05 compared to all other groups, the difference was
clinically significant when compared with MJD, MB, BCM, non-classified). In contrast, the
group composed of non-classified subjects showed the second lowest WOMAC scores among
all subgroups. The non-classified subgroup showed a mild disease (low levels of pain and dis-
ability) and moderate radiographic degeneration (KL grade 2: 36.1%; grade 3: 55.7%).
Regarding the alignment, the MB phenotype is composed mainly of subjects with varus
malalignment. In the other subgroups, varus and valgus malalignment had a similar distribu-
tion. The CP phenotype showed the lowest quadriceps strength while the MB showed the high-
est quadriceps strength (Table 6).
4. Discussion
In the present study patients with KOA were classified into six phenotypes using pre-deter-
mined criteria, with patients meeting the criteria for more than one phenotype classified sepa-
rately into a ‘complex KOA’ group. Phenotype allocation (including complex KOA) was
successful for 84.1% of cases using characteristics that can be measured in a clinical setting.
Subjects classified in the MJD group showed shorter disease duration compared to the
other phenotypes (difference with other groups varying from 0.6 to 1.4 years). This could sug-
gest that these subjects constitute an early KOA subgroup and for this reason have a lower
symptomatology compared with the other phenotypes. Following this hypothesis, the subjects
included in the MJD phenotype should progress and reach (or even overcome) the level of
symptoms showed by the other phenotype in two years.
However, subjects classified in the MJD were selected to have minimal or no progression of
symptoms at two years follow-up. This means that the MJD subjects, despite an increase of
two years in the disease duration, had minimal or no change in symptoms severity. Moreover,
it must be considered that the MJD showed a low prevalence of comorbidities (e.g. depression,
diabetes) (Table 6) that combined with the slow radiographic progression confirms the finding
of previous longitudinal studies that attempted to identify minimal joint disease phenotypes
[32]. Despite the fact that it is not yet clear whether a specific disease mechanism is responsible
for the slow progression rate and mild symptoms that characterize this group, the identifica-
tion of subjects who do not experience symptomatic worsening would be critical for the
Table 5. Ancova models statistics.
WOMAC PAIN WOMAC PHYSICAL FUNCTION
Source Type III Sum
of Squares
F Sig. Type III Sum
of Squares
F Sig.
Corrected Model 53995.769a 27.700 <0.001 48931.351a 27.677 <0.001
Intercept 6447.274 29.768 <0.001 4274.415 21.759 <0.001
Medication use 10216.744 47.171 <0.001 2073.871 10.557 <0.001
Disease duration 1893.982 8.745 0.003 10950.318 55.743 0.001
Phenotype 25373.689 16.736 <0.001 20178.351 14.674 <0.001
Error 127353.416 115507.483
Total 317856.250 281992.661
Corrected Total 181349.185 164438.834
a: R Squared = .298 (Adjusted R Squared = .290)
b: R Squared = .298 (Adjusted R Squared = .287)
df: degree of freedom
https://doi.org/10.1371/journal.pone.0191045.t005
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improvement of resource and treatment allocation which may ultimately result in a reduction
of the clinical cost for KOA.
Subjects classified in the CP phenotype demonstrated the highest levels of pain, disability
and the lowest muscle strength. In this phenotype, the coexistence of cognitive mechanisms
and neurophysiologic alterations such as widespread pain suggests a more global disease
mechanism in which the central nervous system has a primary role and therefore could repre-
sent a target for specific treatments. Carlesso et al., in a study published in 2016[33], suggested
that chronic pain related symptoms are consequences of the knee disease while Neogi et al.
suggested that sensitization and hypersensitivity [34], as well as depression, might be present
before KOA. Despite the contrasting evidence regarding the causality relationship between
KOA and central pain mechanisms; once chronic pain is present, a cognitive-behavioural
intervention and pain education may be worthwhile and may optimize the results of other tra-
ditional intervention such as exercise therapy and joint replacement[35].
The MB phenotype might be a subtype of active subjects, with high levels of muscle
strength, high prevalence of malalignment, lower BMI and low prevalence of other comorbidi-
ties. Furthermore, despite the severe radiographic degeneration present in this phenotype
(60% of the subjects had a K&L grade 3); subjects classified in the MB phenotype have low
levels of pain and disability. These findings suggest the existence of a “healthy” (low levels of
comorbidity, depression, widespread pain) subtype of OA subjects in which biomechanical
factors seem to be the main disease mechanisms. Similar criteria to the specific ones used in
the current study to classify subjects in the MB have been applied in an external cohort to sub-
jects with varus malalignment. The results showed that subjects classified using these criteria
were linked to increased knee medial contact force. [36]. This finding supports our hypothesis
that subjects classified in the MB phenotype are characterized by disrupted biomechanics.
Therefore, interventions aiming to restore an optimal load distribution in the knee such as lat-
erally wedged insoles and gate modification may be more effective if tested on subjects belong-
ing to this phenotype[5].
The I and MD phenotypes showed similar health outcomes. This may be due to the similar-
ity in the hypothesized disease mechanisms. In both these phenotypes, the disease may be due
to inflammatory processes. The metabolic disorder characterizing the MD phenotype have
been shown to be associated with a low-grade inflammation while synovitis, characterizing the
I phenotype, suggests localized more severe inflammation in the knee joint. It may be hypothe-
sized that the involvement of the immune system in the disease process of both these pheno-
types may determine similar outcomes. However, these two phenotypes differ in other
important characteristics. The I phenotype shows a higher prevalence of synovitis/effusion
compared to the MD phenotype which instead presents a higher BMI and a higher prevalence
of metabolic alterations. This suggests that despite the similarity in the outcome, the mecha-
nisms of the disease are different and therefore subjects classified in these phenotypes may
benefit from different treatments. For example, patients classified in the MS may benefit more
from a diet management program and physical activity[37] while subjects with local inflamma-
tion may respond better to local steroid injections[38].
The BCM phenotype also had outcomes similar to the I and MD groups. Classification of
patients in this phenotype was exclusively done based on high levels of bone and cartilage turn-
over biomarkers, relative to other patients in the study sample. Among the biomarkers used to
classify these subjects, sHA was included. This biomarker is normally associated with synovial
activity and may be an indicator of synovitis. However, subjects included in this phenotype
showed minimal or no synovitis and effusion at the MRI. High level of sHA in combination
with high level of sCOMP (sign of cartilage degradation) may be explained by the release of
catabolic enzymes by damaged chondrocytes which degrade the cartilage matrix releasing
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cartilage degradation products that favour synovial activity[39]. Further study will, therefore,
be required to accurately identify the role of specific joint metabolism pathways in the KOA
disease process and their viability and validity as separate phenotypes of the disease. Drugs
aiming to influence bone and cartilage metabolism may see improved their effect if tested in
this specific phenotype[5].
The complex KOA subgroup included all the subjects classified in more than one pheno-
type. A confluence of disease mechanisms may be responsible for disease outcomes in this
group of patients. It was notable that this group reported worse pain and physical functioning
than the other phenotype groups. These subjects may require a more complex and multidisci-
plinary intervention able to target the different mechanism responsible for the disease.
The presence of a group of subjects not classified at the end of the process might imply the
existence of further phenotypes whose disease mechanism has not yet been identified or the
excessive specificity of the applied cut-offs. Subjects classified in this group present a mild dis-
ease with moderate to severe joint damage. This group is primarily similar to the MJD and MB
phenotypes. More accurate classification criteria may enable the classification of these patients
into those groups.
Despite the fact that the study design cannot directly link these phenotypes with different
disease mechanisms; it shows that there are groups of subjects presenting single groups of
characteristics previously associated with different disease mechanisms. The CP phenotype
was solely defined by symptoms rather than by tissue damage and degeneration. However, in
these patients, the severe pain is often associated with a mild involvement of the joint tissue.
When defining KOA as a combination of pain and local tissue damage it is clear how, in these
patients, the alteration in the pain mechanisms can be considered a major disease mechanism.
Therefore, addressing these subjects with tailored interventions aimed to target the specific
risk factors and disease mechanisms may increase the effectiveness of the treatments[5].
Some strengths and limitations of this study need to be highlighted. The cut-off values for
the sensitive and specific inclusion criteria for phenotype membership used in this study were
developed based on evidence extracted from previous studies that focused on the identification
of phenotypes and risk factors in the KOA population[6]. Nevertheless, the arbitrary selection
of cut-offs could lead to classification bias, as the criteria for inclusion into various phenotypes
will not have identical sensitivity and specificity. A two-step classification process was used to
ensure that patients clearly showing signs of one particular phenotype were classified in the
first (specific) step, meaning that more sensitive criteria could be used to classify the remaining
patients without having high rates of false positives for patients clearly belonging to other phe-
notypes as they had already been classified by that point). This approach is exploratory by
nature; further research is needed in order to develop a comprehensive phenotype model
applicable in clinical practice. Moreover, any inferences on the prevalence of individual pheno-
types can only be made with caution. The combination of cut-off values and the inclusion cri-
teria for this particular OAI cohort are likely to influence the prevalence estimates and their
external validity which will have to be replicated in other cohorts.
For the present study, we used the FNIH cohort which was recruited for a case-control
study with specific inclusion criteria. The population in exam is characterized in average by a
mild to moderate disease where subjects with more severe OA (KL = 4) are underrepresented.
Even though the identification of clinical phenotypes in subjects with mild OA may be an
advantage for the development of early targeted interventions, it is possible that this classifica-
tion process would perform differently in a real-life OA population. Further studies perform-
ing similar classification processes in clinical cohorts are needed in order to confirm our
findings and establish their external validity.
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This study utilised a combination of commonly available clinical variables and more
advanced measurements. This classification process presents intrinsic advantages and limita-
tions. The use of clinical variables to classify certain phenotypes strengthens the practical rele-
vance of the analyses, while it implies that some of the proposed underlying disease
mechanisms were not measured directly. For example, the MB phenotype criteria did not
include a direct measurement of knee joint load. The opposite can be said for phenotypes
defined using more advanced procedures (e.g. MRI, bone and cartilage biomarkers) which are
not routinely performed in the OA patients’ management. This is likely to limit the clinical
applicability of this classification process. Further studies are needed to justify the use of such
measurements. It is possible that the benefits, both economic and clinical, of phenotype-spe-
cific interventions will overcome the costs of these practices increasing their clinical relevance
and applicability.
In conclusion, this study has succeeded in classifying groups of subjects characterized by
specific clinical characteristics that may be linked to different disease mechanisms and there-
fore likely to represent distinct clinical phenotypes. However, longitudinal studies analyzing
the onset and development of KOA are needed in order to understand whether these clinical
characteristics may be considered risk factors for incidence of KOA or the result of different
disease paths. In addition, a complex KOA group of patients meeting the inclusion criteria for
more than one phenotype was identified. This is a vital step towards the optimization of treat-
ment allocation. While personalized medicine offers great potential to improve treatment
effectiveness, the greater need for individual profiling needs to be balanced against the
resources available in increasingly stretched healthcare systems worldwide. Identifying
homogenous subgroups from within a diagnostic population using clinical information might
provide this balance and improve treatment allocation for the individual patients concerned.
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